Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

S100 B: A new concept in neurocritical care.

Rezaei O, Pakdaman H, Gharehgozli K, Simani L, Vahedian-Azimi A, Asaadi S, Sahraei Z, Hajiesmaeili M.

Iran J Neurol. 2017 Apr 4;16(2):83-89. Review.

2.

Usefulness of S100B protein in neurological disorders.

Yardan T, Erenler AK, Baydin A, Aydin K, Cokluk C.

J Pak Med Assoc. 2011 Mar;61(3):276-81. Review.

3.

S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury.

Goyal A, Failla MD, Niyonkuru C, Amin K, Fabio A, Berger RP, Wagner AK.

J Neurotrauma. 2013 Jun 1;30(11):946-57. doi: 10.1089/neu.2012.2579.

4.

GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome.

Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H.

J Neurotrauma. 2004 Nov;21(11):1553-61.

PMID:
15684648
5.

The neurotrophic protein S100B: value as a marker of brain damage and possible therapeutic implications.

Kleindienst A, Hesse F, Bullock MR, Buchfelder M.

Prog Brain Res. 2007;161:317-25. Review.

PMID:
17618987
6.

Neurobiochemical markers of brain damage in cerebrospinal fluid of acute ischemic stroke patients.

Brouns R, De Vil B, Cras P, De Surgeloose D, Mariën P, De Deyn PP.

Clin Chem. 2010 Mar;56(3):451-8. doi: 10.1373/clinchem.2009.134122. Epub 2009 Dec 3.

7.

Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children.

Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RS, Ruppel RA, Kochanek PM.

Pediatrics. 2002 Feb;109(2):E31.

PMID:
11826241
8.

Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury.

Hayakata T, Shiozaki T, Tasaki O, Ikegawa H, Inoue Y, Toshiyuki F, Hosotubo H, Kieko F, Yamashita T, Tanaka H, Shimazu T, Sugimoto H.

Shock. 2004 Aug;22(2):102-7.

PMID:
15257081
9.

Validation of serum markers for blood-brain barrier disruption in traumatic brain injury.

Blyth BJ, Farhavar A, Gee C, Hawthorn B, He H, Nayak A, Stöcklein V, Bazarian JJ.

J Neurotrauma. 2009 Sep;26(9):1497-1507. doi: 10.1089/neu.2008-0738.

10.

Association between S100B Levels and Long-Term Outcome after Aneurysmal Subarachnoid Hemorrhage: Systematic Review and Pooled Analysis.

Lai PM, Du R.

PLoS One. 2016 Mar 23;11(3):e0151853. doi: 10.1371/journal.pone.0151853. eCollection 2016. Review.

11.

Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24h) time-point.

Rainey T, Lesko M, Sacho R, Lecky F, Childs C.

Resuscitation. 2009 Mar;80(3):341-5. doi: 10.1016/j.resuscitation.2008.11.021. Epub 2009 Jan 15.

PMID:
19150161
12.

Elevated serum ubiquitin carboxy-terminal hydrolase L1 is associated with abnormal blood-brain barrier function after traumatic brain injury.

Blyth BJ, Farahvar A, He H, Nayak A, Yang C, Shaw G, Bazarian JJ.

J Neurotrauma. 2011 Dec;28(12):2453-62. doi: 10.1089/neu.2010.1653. Epub 2011 Aug 8.

PMID:
21428722
13.

Elevated levels of cerebrospinal fluid S100B are associated with brain injury and unfavorable outcomes in children with central nervous system infections.

Peng QL, Tao SH, Yu N, Zhou XZ, Peng YZ, Fu N.

Int J Neurosci. 2017 Jan;127(1):1-9. Epub 2016 Jan 25.

PMID:
26710878
14.

Dynamics of S100B release into serum and cerebrospinal fluid following acute brain injury.

Kleindienst A, Meissner S, Eyupoglu IY, Parsch H, Schmidt C, Buchfelder M.

Acta Neurochir Suppl. 2010;106:247-50. doi: 10.1007/978-3-211-98811-4_46.

PMID:
19812958
15.

Intraventricular infusion of the neurotrophic protein S100B improves cognitive recovery after fluid percussion injury in the rat.

Kleindienst A, Harvey HB, Rice AC, Müller C, Hamm RJ, Gaab MR, Bullock MR.

J Neurotrauma. 2004 May;21(5):541-7.

PMID:
15165362
16.

S100B and NSE as useful postmortem biochemical markers of traumatic brain injury in autopsy cases.

Ondruschka B, Pohlers D, Sommer G, Schober K, Teupser D, Franke H, Dressler J.

J Neurotrauma. 2013 Nov 15;30(22):1862-71. doi: 10.1089/neu.2013.2895. Epub 2013 Sep 19.

PMID:
23796187
17.

S100B protein may detect brain death development after severe traumatic brain injury.

Egea-Guerrero JJ, Murillo-Cabezas F, Gordillo-Escobar E, Rodríguez-Rodríguez A, Enamorado-Enamorado J, Revuelto-Rey J, Pacheco-Sánchez M, León-Justel A, Domínguez-Roldán JM, Vilches-Arenas A.

J Neurotrauma. 2013 Oct 15;30(20):1762-9. doi: 10.1089/neu.2012.2606. Epub 2013 Aug 28.

18.

Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury.

Nylén K, Ost M, Csajbok LZ, Nilsson I, Hall C, Blennow K, Nellgård B, Rosengren L.

Acta Neurochir (Wien). 2008 Mar;150(3):221-7; discussion 227. doi: 10.1007/s00701-007-1489-2. Epub 2008 Jan 14.

PMID:
18193148
19.

Role of the S100B serum biomarker in the treatment of children suffering from mild traumatic brain injury.

Filippidis AS, Papadopoulos DC, Kapsalaki EZ, Fountas KN.

Neurosurg Focus. 2010 Nov;29(5):E2. doi: 10.3171/2010.8.FOCUS10185. Review.

PMID:
21039136
20.

Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B.

Bellander BM, Olafsson IH, Ghatan PH, Bro Skejo HP, Hansson LO, Wanecek M, Svensson MA.

Acta Neurochir (Wien). 2011 Jan;153(1):90-100. doi: 10.1007/s00701-010-0737-z. Epub 2010 Aug 6.

Supplemental Content

Support Center